Boosting the chances to improve stroke treatment

Stroke

Volumn 41, Issue 3, 2010, Pages

  Cobo, Erik ^a   Secades, Julio J ^b   Miras, Francesc ^a   González, José Antonio ^a   Saver, Jeffrey L ^c   Corchero, Cristina ^a   Rius, Roser ^a   Dàvalos, Antoni ^d  

^a UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^b Sant Joan Despi   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Analysis; Biostatistics; Clinical trials; Scales; Stroke management; Stroke recovery

Indexed keywords

ARTICLE; BARTHEL INDEX; CONTROLLED STUDY; CONVALESCENCE; DATA ANALYSIS; HUMAN; INFORMATION PROCESSING; INTROSPECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RATING SCALE; STROKE;

CLINICAL TRIALS AS TOPIC; HUMANS; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME;

EID: 77649155686     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.567404     Document Type: Article

References (31)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke Lancet. 2008;371: 1612-1623.
2. th century. Stroke. 2001;32: 1349-1359.
3. Bolland K, Sooriyarachchi MR, Whitehead J. Sample size review in a head injury trial with ordered categorical responses. Stat Med. 1998;17: 2835-2847.
4. Wardlaw JM, Sandercock PAG, Warlow CP, Lindley RI. Trials of thrombolysis in acute ischemic stroke. Does the choice of primary outcome measure really matter? Stroke. 2000;31:1133-1135.
5. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055-3062.
6. Young FB, Lees KR, Weir CJ; for the GAIN trial Steering Committee and Investigators. Strengthening acute stroke trials though optimal use of disability end points. Stroke. 2003;34:2676-2680.
7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
8. Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T, Lyden P, Grotta J; for the National Institute of Neurological disorders and stroke t-PA stroke trial study group. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological disorders and stroke t-PA stroke trial. Stroke. 1996;27: 2136-2142.
9. Lees KR, Zivin JA, Askwood T, Dávalos A, Davis SM, Diener HC, Grott J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
10. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S; for the STAIR group. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke. 2007;38:245-248.
11. Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, Lopez S, Cobo E, Warach S, Sherman D, Clark WM, Lozano R. Oral citicoline in acute ischemic stroke:an individual patient data pooling analysis of clinical trials. Stroke. 2002;33:2850-2857.
12. Lefevre-Colau MM, Fayad F, Rannou F, Fermanina J, Coriat F, Mace Y, Revel M, Poiradeau S. Frequency and interrelations of risk factors for chronic low back pain in a primary care setting. Plos One 2009;4:e4874.
13. Briand S, Beresniak A, Nguyen T, Yonli T, Duru G, Kambire Ch, Perea W; for the Yellow fever risk assessment group (YF-RAG). PLOS neglected tropical diseases 2009;3:e483.
14. Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Abedi-Ardekani B, Merat S, Naseri-Moghaddam S, Semnani S, Sepehr A, Wakefield J, Moller H, Abnet CC, Dawsey SM, Boffetta P, Malekzadeh R. Socio-economic status and oesophageal cancer: results from a population-based case-control study in a high-risk area. Int J Epidemiol. 2009;38:978-988
15. Committee for proprietary medicinal products of the European Agency for the evaluation of Medicinal Products. Points to consider on clinical investigation of Medicinal products for the treatment of acute stroke. 2001;CPMP/EWP/560/98.
16. Bolland K, Whitehead J, Cobo E, Secades J. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of Citicoline. Pharm Stat. 2009;8:136-149.
17. Song F, Jerosch-Herold C, Holland R, Drachier M, Mares K, Harvey I. Statistical methods for analysing Barthel scores in trials of poststroke interventions: a review and computer simulations. Clin Rehabil. 2006;20: 347-356.
18. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006;5:603-612.
19. König IR, Ziegler A, Bluhmki E, Hacke W, Bath PM, Sacco RL, Diener HC, Weimar C; Virtual International Stroke Trials Archive (VISTA) Investigators. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke. 2008;39:1665-1666.
20. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, Hårdemark HG, Rodichok L; for the SAINT I and II Investigators Stroke. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39:1751-1758.
21. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T; for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-694. (Pubitemid 32322245)
22. Montes G, Fernandez JA, Prada A, Polonio R, Rodriguez D, Perula LA. Fiabilidad en la medición de la presión arterial:paciente frente a profesionales de atención primaria. Atención Primaria. 2000;25: 27-35.
23. Tebe C, Berra S, Herdman M, Aymerich M, Alonso J, Rajmil L. Fiabilidad y validez de la versión española del KIDSCREEN-52 para población infantil y adolescente. Med Clin (Barc). 2008;130: 650-654.
24. Bossuyt P, Reitsma J, Bruns D, Gatsonis C, Glasziou P, Irwig L, Lijmer J, Moher D, Rennie D, De Vet H. Towards complete and accurate reporting of studies of diagnostic accuracy:The STARD initiative. Clin Chem. 2003;49:1-6. (Pubitemid 36078546)
25. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches. Int J Stroke. 2008;3: 78-84.
26. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke. 2007;38:3205-3212.
27. Newcombe RG. Confidence intervals for an effect size measure based on the Mann-Whitney statistic. Part 1: General issues and tail-area-based methods. Statist Med. 2006;25:543-557.
28. Acion L, Peterson JJ, Temple S, Arndt S. Probabilistic index: an intuitive non-parametric approach to measuring the size of treatment effects. Statist Med. 2006;25:591-602.
29. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079-1087.
30. Huang P, Tilley BC, Woolson RF, Lipsitz S. Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics. 2005;61:532-539.
31. Ahn C, Jung S. Efficiency of general estimating equations estimators of slopes in repeated measurements: Adding subjects or adding measurements? Drug Inform J. 2003;37:309-316.